TypeName: Business Offer
Offer Date:2018/09/29
Country: United States
Summary: This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The IC50 value is 200 pM in ALK enzymatic assays and 25 nM in cells. It less potently inhibits IGF-1R, InsR, and STK22D and IC50 value is 8, 7, and 23 nM. LDK378 is also minimally effective against a panel of other kinases. In Sep 2016, Interim adverse events and efficacy data from phase III ASCEND-4 trial in non small cell lung cancer released by Novartis. In Oct 2016, efficacy data from the phase III ASCEND-3 and ASCEND-5 trial in non small cell lung cancer was presented.
https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html
Description: [RequestDescription]
OfferId: 2136
Name:Alex Brown
Telphone:
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
